Rossi Alfredo, Fortuna Maria Caterina, Caro Gemma, Pranteda Giulia, Garelli Valentina, Pompili Umberto, Carlesimo Marta
Department of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
Dermatology, "Sapienza" University of Rome, II School, Rome, Italy.
J Cosmet Dermatol. 2017 Dec;16(4):537-541. doi: 10.1111/jocd.12308. Epub 2017 Feb 2.
Chemotherapy-induced alopecia (CIA) is probably one of the most shocking aspects for oncological patients and underestimated by physicians. Among hair loss risk factors, there are treatment-related aspects such as drug dose, administration regimen, and exposure to X-rays, but also patient-related characteristics. To the best of our knowledge, no guidelines are available about CIA management.
With this study, based on literature background and our clinical experience, we would like to propose a list of actions in order to estimate the risk of hair loss before starting chemotherapy and to manage this condition before, during, and after drug administration and to create a sort of practical guide for dermatologists and oncologists.
There is an urgent need for prospective studies to clarify the mechanistic basis of alopecia associated with these drugs and consequently to design evidence-based management strategies.
化疗引起的脱发（CIA）可能是肿瘤患者最震惊的方面之一，且被医生所低估。在脱发风险因素中，有与治疗相关的方面，如药物剂量、给药方案和X射线暴露，也有患者相关特征。据我们所知，目前尚无关于CIA管理的指南。
通过本研究，基于文献背景和我们的临床经验，我们想提出一系列措施，以便在开始化疗前评估脱发风险，并在药物给药前、给药期间和给药后对这种情况进行管理，为皮肤科医生和肿瘤学家创建一种实用指南。
迫切需要进行前瞻性研究，以阐明与这些药物相关的脱发的机制基础，并因此设计基于证据的管理策略。
